Crossref
Comparison of thalidomide versus apatinib for prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation: a retrospective study
SCIREA Journal of Clinical Medicine · 2023
DOI: 10.54647/cm321042 ↗Kurz gefasst
Fachartikel in der Zeitschrift SCIREA Journal of Clinical Medicine, 2023. Verfasst von Geng Song und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Song, G., Zhang, F., & Cheng, H. (2023). Comparison of thalidomide versus apatinib for prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation: a retrospective study. SCIREA Journal of Clinical Medicine. https://doi.org/10.54647/cm321042
Vancouver
Song G, Zhang F, Cheng H. Comparison of thalidomide versus apatinib for prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation: a retrospective study. SCIREA Journal of Clinical Medicine. 2023. doi:10.54647/cm321042
BibTeX
@article{Song2023,
author = {Song, Geng and Zhang, Fei-Fei and Cheng, Huai-Dong},
title = {Comparison of thalidomide versus apatinib for prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation: a retrospective study},
journal = {SCIREA Journal of Clinical Medicine},
year = {2023},
doi = {10.54647/cm321042}
}
EUVIMED